JP2016531949A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531949A5
JP2016531949A5 JP2016546191A JP2016546191A JP2016531949A5 JP 2016531949 A5 JP2016531949 A5 JP 2016531949A5 JP 2016546191 A JP2016546191 A JP 2016546191A JP 2016546191 A JP2016546191 A JP 2016546191A JP 2016531949 A5 JP2016531949 A5 JP 2016531949A5
Authority
JP
Japan
Prior art keywords
salt
composition
olopatadine
mometasone
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016546191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531949A (ja
JP6419195B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/065035 external-priority patent/WO2015049665A1/en
Publication of JP2016531949A publication Critical patent/JP2016531949A/ja
Publication of JP2016531949A5 publication Critical patent/JP2016531949A5/ja
Application granted granted Critical
Publication of JP6419195B2 publication Critical patent/JP6419195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016546191A 2013-10-04 2014-10-03 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療 Active JP6419195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3174MU2013 2013-10-04
IN3174MUM2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076047A Division JP6768733B2 (ja) 2013-10-04 2018-04-11 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Publications (3)

Publication Number Publication Date
JP2016531949A JP2016531949A (ja) 2016-10-13
JP2016531949A5 true JP2016531949A5 (enExample) 2016-11-24
JP6419195B2 JP6419195B2 (ja) 2018-11-07

Family

ID=51982657

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016546191A Active JP6419195B2 (ja) 2013-10-04 2014-10-03 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP2018076047A Active JP6768733B2 (ja) 2013-10-04 2018-04-11 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP2020028523A Pending JP2020097624A (ja) 2013-10-04 2020-02-21 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018076047A Active JP6768733B2 (ja) 2013-10-04 2018-04-11 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP2020028523A Pending JP2020097624A (ja) 2013-10-04 2020-02-21 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Country Status (12)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP4272839A3 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN105792828A (enExample)
HK (1) HK1215674A1 (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302A1 (enExample)
RU (1) RU2686670C2 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
HK1215674A1 (zh) * 2013-10-04 2016-09-09 Glenmark Pharmaceuticals Limited 结合使用莫米松和奥洛他定治疗过敏性鼻炎
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN109475495B9 (zh) * 2017-06-28 2023-01-03 格兰马克专业公司 用于治疗鼻炎的分配装置和药物组合物
HUE071622T2 (hu) * 2018-02-23 2025-09-28 Glenmark Specialty Sa Allergiás Rhinitis kezelése gyermekgyógyászati alanyoknál mometazon és olopatadin kombinációjával
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
ES2284531T3 (es) 1999-10-08 2007-11-16 Schering Corporation Tratamiento nasal topico usando desloratadina y furoato de mometasona.
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
WO2004043470A1 (en) 2002-11-12 2004-05-27 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20060110328A1 (en) 2004-11-24 2006-05-25 Cagle Gerald D Method of delivering nasal spray
EP1919450B1 (en) * 2005-09-01 2014-06-11 Meda AB Antihistamine- and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
JP2009518300A (ja) 2005-12-02 2009-05-07 エラン ファーマ インターナショナル リミテッド モメタゾン組成物ならびにその作製方法および使用方法
BRPI0710654B1 (pt) 2006-04-21 2021-11-03 Toko Yakuhin Kogyo Kabushiki Kaisha Preparação de adesivo para pele/mucosa do tipo gel, pulverizável, e sistema de administração usando a preparação
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
KR20110045004A (ko) * 2008-07-15 2011-05-03 쉐링 코포레이션 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물
WO2010025236A1 (en) 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
WO2011008923A2 (en) 2009-07-17 2011-01-20 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
PL2736491T3 (pl) 2011-01-04 2017-09-29 Bausch & Lomb Incorporated Kompozycje bepotastyny
US20150275147A1 (en) 2012-10-25 2015-10-01 Novozymes A/S Method for Manual Dish Wash
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MY191380A (en) 2013-09-13 2022-06-21 Glenmark Specialty Sa Stabilized fixed dose drug composition having mometasone and olopatadine
HK1215674A1 (zh) * 2013-10-04 2016-09-09 Glenmark Pharmaceuticals Limited 结合使用莫米松和奥洛他定治疗过敏性鼻炎

Similar Documents

Publication Publication Date Title
JP2016531949A5 (enExample)
JP2016523862A5 (enExample)
JP2010132695A5 (enExample)
EP4335418A3 (en) Compositions and methods for treating pterygium
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
ME02841B (me) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
EA201890196A1 (ru) Композиция для устранения заложенности носа, обладающая противовирусным действием
PH12016500433A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
JP2015534562A5 (enExample)
RU2015128496A (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
EA201791780A1 (ru) Ингаляционный раствор тиотропия для небулайзерного распыления
DOP2022000093A (es) Inhibidores de adrenoreceptor adrac2
BR112015025804A2 (pt) derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
EP3424512A4 (en) USE OF ALGIN SULFATE IN THE MANUFACTURE OF MEDICAMENTS AND HEALTH CARE PRODUCTS FOR THE PREVENTION AND TREATMENT OF ILLNESSES DUE TO HUMAN PAPILLOMA VIRUSES
JP2017505809A5 (enExample)
JP2016502991A5 (enExample)
JP2014520874A5 (enExample)
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
JP2019529569A5 (enExample)
JP2017061488A5 (enExample)
EA201792565A1 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
JP2016175884A5 (enExample)
HRP20250411T1 (hr) Liječenje alergijskog rinitisa kod pedijatrijskih subjekata kombinacijom mometazona i olopatadina
JP2015120650A5 (enExample)